Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential.

Ferrero V, Ribichini F, Pesarini G, Brunelleschi S, Vassanelli C.

Drugs. 2007;67(9):1243-55. Review.

PMID:
17547469
2.

Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.

Kuchulakanti P, Waksman R.

Drugs. 2004;64(21):2379-88. Review.

PMID:
15481997
3.

A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.

PMID:
19377384
4.

Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study).

Ferrero V, Ribichini F, Rognoni A, Marino P, Brunelleschi S, Vassanelli C.

Am J Cardiol. 2007 Apr 15;99(8):1082-6.

PMID:
17437731
5.

Prevention of restenosis with antioxidants: mechanisms and implications.

Tardif JC, Grégoire J, L'Allier PL.

Am J Cardiovasc Drugs. 2002;2(5):323-34. Review.

PMID:
14727962
6.

[Optimal platelet inhibition after coronary stent implantation. Current status].

Silber S, Hoffmeister HM, Bode C.

Herz. 2008 Jun;33(4):244-53. doi: 10.1007/s00059-008-3138-9. Review. German.

PMID:
18581073
7.

Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?

Jimenez-Valero S, Moreno R, Sanchez-Recalde A, Galeote G, Calvo L, Viana A, Lopez de Sá E, López-Sendón J.

Ther Adv Cardiovasc Dis. 2008 Jun;2(3):137-46. doi: 10.1177/1753944708090573. Review.

PMID:
19124417
8.

Dexamethasone and restenosis after coronary stent implantation: new indication for an old drug?

Radke PW, Weber C, Kaiser A, Schober A, Hoffmann R.

Curr Pharm Des. 2004;10(4):349-55. Review.

PMID:
14965196
9.

Emergency percutaneous coronary intervention (PCI) for the care of patients with ST-elevation myocardial infarction (STEMI).

Morrison DA, Berman M, El-Amin O, McLaughlin RT, Bates ER.

Minerva Cardioangiol. 2007 Oct;55(5):593-623. Review.

PMID:
17912165
10.

Clinical outcomes of dialysis patients after implantation of DES: meta analysis and systematic review of literature.

Athappan G, Ponniah T.

Minerva Cardioangiol. 2009 Jun;57(3):291-7. Review.

PMID:
19513010
11.

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators..

Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528.

12.

Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.

Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A.

Circulation. 2007 Jun 26;115(25):3181-8.

13.

Drug-eluting coronary stents: many meta-analyses, little benefit.

[No authors listed]

Prescrire Int. 2009 Apr;18(100):70-4.

PMID:
19585727
14.

Effect of a novel drug-eluted balloon coated with genistein before stent implantation in porcine coronary arteries.

Sheiban I, Anselmino M, Moretti C, Biondi-Zoccai G, Galloni M, Vignolini C, Mattoni M, Sciuto F, Omedè P, Trevi GP.

Clin Res Cardiol. 2008 Dec;97(12):891-8. doi: 10.1007/s00392-008-0705-2.

PMID:
18777002
15.

Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions.

Ribichini F, Ferrero V, Feola M, Rognoni A, Brunelleschi S, Vacca G, Vassanelli C.

J Interv Cardiol. 2007 Jun;20(3):209-13.

PMID:
17524113
16.

Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects.

Li JJ, Li J, Nan JL, Li Z, Zhen X, Mu CW, Dai J, Zhang CY.

Med Hypotheses. 2007;69(5):1004-9.

PMID:
17499449
17.

Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis.

Ribichini F, Joner M, Ferrero V, Finn AV, Crimins J, Nakazawa G, Acampado E, Kolodgie FD, Vassanelli C, Virmani R.

J Am Coll Cardiol. 2007 Jul 10;50(2):176-85.

18.
19.

Understanding the drug-eluting stent trials.

Coolong A, Kuntz RE.

Am J Cardiol. 2007 Sep 3;100(5A):17K-24K. Review.

PMID:
17719349
20.

Safety of drug-eluting stents.

Windecker S, Jüni P.

Nat Clin Pract Cardiovasc Med. 2008 Jun;5(6):316-28. doi: 10.1038/ncpcardio1189. Review.

PMID:
18414453
Items per page

Supplemental Content

Support Center